Kristi Rosa | Authors


Nivo/Ipi Induces Promising Response in Advanced tTMB- and bTMB-High Solid Tumors

April 11, 2022

Results from the phase 2 CheckMate-848 study show that nivolumab in combination and ipilimumab may be effective for the treatment of advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies.